Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michel Porzio
Effect of One-Year Lumacaftor–ivacaftor Treatment on Glucose Tolerance Abnormalities in Cystic Fibrosis Patients
Journal of Cystic Fibrosis
Child Health
Pulmonary
Pediatrics
Perinatology
Respiratory Medicine
Related publications
Cost Effectiveness of Ivacaftor and Lumacaftor Combination for the Treatment of Patients With Cystic Fibrosis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Glucose Tolerance in Cystic Fibrosis.
Archives of Disease in Childhood
Child Health
Pediatrics
Perinatology
Glucose Tolerance During Pulmonary Exacerbations in Children With Cystic Fibrosis
PLoS ONE
Multidisciplinary
Long-Term Computed Tomographic Changes in Cystic Fibrosis Patients Treated With Ivacaftor
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Lumacaftor/Ivacaftor Reduces Pulmonary Exacerbations in Patients Irrespective of Initial Changes in FEV1
Journal of Cystic Fibrosis
Child Health
Pulmonary
Pediatrics
Perinatology
Respiratory Medicine
GP273 Corkambi: One Year Outcomes of Orkambi on Cystic Fibrosis Paediatric Patients in Cork University Hospital
Insulin Responses to Intravenous Glucose and the Hyperglycemic Clamp in Cystic Fibrosis Patients With Different Degrees of Glucose Tolerance
Pediatric Research
Child Health
Pediatrics
Perinatology
Bridging for Lung Transplantation With Lumacaftor/Ivacaftor
Breathe
Pulmonary
Respiratory Medicine
Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis
Journal of Pediatric Pharmacology and Therapeutics
Child Health
Pediatrics
Perinatology
Pharmacology